Ocular Therapeutix
OCUL
OCUL
248 hedge funds and large institutions have $2.33B invested in Ocular Therapeutix in 2025 Q4 according to their latest regulatory filings, with 58 funds opening new positions, 104 increasing their positions, 60 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
6% more capital invested
Capital invested by funds: $2.2B → $2.33B (+$125M)
18.23% less ownership
Funds ownership: 108.15% → 89.92% (-18%)
36% less funds holding in top 10
Funds holding in top 10: 11 → 7 (-4)
Holders
248
Holding in Top 10
7
Calls
$47.8M
Puts
$21M
Top Buyers
| 1 | +$61.3M | |
| 2 | +$29.3M | |
| 3 | +$26.5M | |
| 4 |
D.E. Shaw & Co
New York
|
+$12.6M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$12.4M |
Top Sellers
| 1 | -$71M | |
| 2 | -$46.9M | |
| 3 | -$43.5M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$39.2M |
| 5 |
Morgan Stanley
New York
|
-$19.3M |
